Edesa Biotech, Inc. (EDSA)

Edesa Biotech Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2018
Cash & Equivalents	5.36	7.09	7.84	7.21	3.37
Cash & Cash Equivalents	5.36	7.09	7.84	7.21	3.37
Cash Growth	-24.39%	-9.55%	8.67%	114.24%	-48.71%
Receivables	0.63	1.26	3.3	0.09	0.01
Other Current Assets	0.45	0.75	0.95	0.8	0.02
Total Current Assets	6.44	9.09	12.09	8.1	3.39
Property, Plant & Equipment	0.1	0.03	0.11	0.17	0.01
Long-Term Investments	0.17	0.17	0	0	0
Goodwill and Intangibles	2.18	2.28	2.38	2.48	0
Total Long-Term Assets	2.45	2.48	2.49	2.66	0.01
Total Assets	8.89	11.58	14.58	10.76	3.4
Accounts Payable	1.75	2.17	1.43	1.49	0.18
Current Debt	0.07	0.02	0.08	0.07	0
Other Current Liabilities	0	-0.04	-0.05	-0.03	0
Total Current Liabilities	1.82	2.14	1.46	1.53	0.18
Long-Term Debt	0.02	0	0.02	0.09	0
Other Long-Term Liabilities	0	0.04	0.05	0.03	0
Total Long-Term Liabilities	0.02	0.04	0.07	0.12	0
Total Liabilities	1.84	2.18	1.53	1.65	0.18
Total Debt	0.09	0.02	0.1	0.16	0
Debt Growth	397.96%	-80.90%	-39.51%	-	-
Retained Earnings	-52.42	-44.04	-26.5	-13.13	-3.76
Comprehensive Income	-0.21	-0.21	-0.21	-0.29	-0.43
Shareholders' Equity	7.05	9.39	13.06	6.63	3.21
Net Cash / Debt	5.27	7.07	7.74	7.05	3.37
Net Cash / Debt Growth	-25.52%	-8.63%	9.79%	109.36%	-48.71%
Net Cash Per Share	1.84	3.37	4.49	5.73	7.27
Working Capital	4.61	6.95	10.63	6.57	3.21
Book Value Per Share	2.47	4.48	7.57	5.39	6.95

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).